Breast cancer
Management of HER2+ MBCErika (47 years old)
Erika is a 47-year-old waitress and was diagnosed with HR+ HER2+ MBC 30 months ago. She has a follow-up visit today.
Assessment summary
- Premenopausal
- No relevant comorbidities
- ECOG PS: 1
- Medical history:
- 30 months ago: diagnosis de novo HR+ HER2+ MBC
- Tumour biology (breast lesion): invasive ductal carcinoma, ER 100%, PgR 100%, HER2 IHC 2+ with amplification (ISH+)
- First-line treatment for bone and lung metastases:
- Paclitaxel + trastuzumab-pertuzumab for 22 months (paclitaxel stopped due to neuropathy after 18 infusions)
- Maintenance dual blockade (trastuzumab-pertuzumab) and endocrine therapy (AI + LHRH analogue)
- Systematic PET-CT during follow-up: multiple bone progression